Nanomaterials in cosmetics – The next priority of the Commission?

Since a number of new developments have taken place in the area of nanomaterial safety research, the EC Scientific Committee on Consumer Safety (SCCS) has updated its Guidance in October 2019 to ensure compliance of nanomaterials intended for use as cosmetic ingredients under the current EU legislation (EC No 1223/2009). We have provided a summary […]
Read More

Alternatives to the use of vertebrate animals in ecotoxicity testing – Progress so far

There is a growing need for alternatives to the use of vertebrate animals in the hazard assessment of chemicals. Many regulatory frameworks, including REACH (e.g., the European Union’s regulation on the Registration, Evaluation, Authorisation and Restriction of Chemicals), stipulate that vertebrate tests should be conducted only as a last resort. Nevertheless, there is still a […]
Read More

SCCS Guidance on the Safety Assessment of Nanomaterials in Cosmetics

The European Commission’s Scientific Committee on Consumer Safety (SCCS) published in November 2019 an up-to-date revision of the existing Guidance on the Safety Assessment of Nanomaterials (NMs) used in Cosmetic Products (SCCS/1484/12). The discussion to revise the Guidance on safety assessment of NMs started in May 2017 within a dedicated SCCS working group and aimed at providing key recommendations for safety of NM used in cosmetics including data requirements.
Read More

Requirement of second species testing for evaluating developmental toxicity potential

Over the last decade, there has been ongoing debate on the regulatory requirement of a second-species testing requirement to identify developmental toxicity. A recent article by Braakhuis et al. (2019) has questioned the reproducibility of developmental toxicity results and the comparison approach using NOAELs. The current insight attempts to present the state-of-the-art information on the ongoing discussion.
Read More

Mutagenicity assessment of drug impurities according to the ICH M7 (R1) guideline and the role of expert review

The evaluation of the genotoxicity potential of drug impurities has been the focus of regulatory recommendations issued by the United States Food and Drug Administration (FDA, 2008), European Medicines Agency (EMA, 2006 and 2010), and International Conference for Harmonization (ICH, 2014, 2015). In 2017, the ICH M7 issued a revised guideline providing a framework for the assessment and control of mutagenic impurities in pharmaceuticals.
Read More

Natural ingredients, inherently safe?

The Executive Director of the Cosmetics Ingredient Review (CIR) addresses the myth of the perceived greater safety of natural versus synthetic and the importance of an expert safety assessment of ingredients in the journal Cosmetics & Toiletries.
Read More

Adopting New Approach Methodologies (NAM) in the next generation risk assessment (NGRA)

The term “new approach methodologies” (NAMs) has been emerged as a descriptive reference to any non-animal-based approaches that can be used to provide information in the context of chemical hazard and risk assessment. These new approaches include integrated approaches to testing and assessment (IATAs), defined approaches for data interpretation, and performance-based evaluation of test methods.
Read More